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Background: Para-phenylenediamine (PPD) is the main allergen causing adverse reactions to hair dyes and a
frequent cause of occupational-related skin sensitization among hairdressers and beauticians. The immunologic
mechanism of the disease relies on the production of inflammatory cytokines by allergen-specific T cells, while
regulatory T cells are thought to down-modulate the allergic response. This study was aimed at investigating the
expression of effector or regulatory cytokines in exposed subjects in order to verify whether different cytokine
profiles might predict distinct clinical outcomes. Peripheral blood mononuclear cells (PBMC) from 21 subjects
occupationally exposed or not (10) to PPD were kept in short term cultures in the presence of optimized concentrations
of NiSO4 × 6H2O or PPD. The production of IFN-γ and IL-10 elicited by antigens were analyzed by the ELISpot assay.
Results: The presence of IFN-γ responses toward PPD was significantly correlated with a positive patch test (P = 0.002)
and allergic symptoms, while IL10 responses were invariably found in PPD-exposed but clinically asymptomatic subjects
with negative patch testing. We found concordance between the different cytokine profiles and patch test results.
No false-positive results were found for the different cytokine profiles induced by PPD, resulting in 100% specificity.
The sensitivity of the test was 87.5% (95% CI 65.9-100.0) with an overall test accuracy of 93.3%. Although larger
prospective-retrospective studies are necessary to validate the predictive potential of the test, the negative
and positive predicted values for PPD in this study were NPV = 87.5% and PPV = 100%, respectively.
Conclusions: These data indicate that distinct cytokine profiles are associated with different clinical manifestations.
The test, which is based on a simple and rapid profiling of cytokine responses by T lymphocytes against allergens, has
proven to be a promising laboratory tool, useful for both the identification of previous contact with allergens and the
etiologic diagnosis of contact allergies as well as capable of predicting the clinical outcome (development of an
allergic or tolerant response).
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Para-phenylenediamine (PPD) and related para-amino
compounds represent the most common active reagents
present in permanent dyes, which are widely used in a
variety of industrial processes. PPD and related agents
are potent contact allergens [1-5]. The relevance of PPD
in the pathogenesis of delayed-type occupational skin al-
lergy has increased considerably in recent years [6] and has
been recognised as the main allergen causing severe ad-
verse reactions to hair dyes [7,8]. In addition, PPD-related
substances are also present in textile dyes [9], leather
dyes [10], fur dyes, and ‘black’ rubbers [11]. Occupational
sensitization to PPD and related substances presents the
highest prevalence among hairdressers [12] and beauti-
cians, in both men (15.4%) and women (14.7%) [5]. How-
ever, severe allergic reactions to PPD have been also
reported in children [6]. In addition, the increasing use of
permanent makeup or tattoos has recently become a fur-
ther cause of PPD skin sensitization [13,14].
The clinical outcome of allergic contact dermatitis (ACD)
includes contact urticaria, lymphomatoid reactions and
even anaphylaxis [15], causing a considerable social and
economic burden [7].
PPD-induced allergic disorders are mostly caused by
skin contact to low molecular weight haptens. In fact,
the effects of PPD on immune cells is thought to arise
from its chemical instability under aqueous conditions.
The ensuing auto-oxidation of the molecule leads to the
formation of an electrophilic primary quinonediimine inter-
mediate, which is susceptible to sequential self-conjugation.
A rearrangement product of the oxido-conjugation reac-
tion gives rise to the trimeric Bandrowski’s base, which is
also immunogenic by itself [16,17].
The process of hypersensitivity in ACD requires a first
sensitization phase, in which the hapten–carrier complex
leads to T-cell activation [18-20] and is followed by the
local release of pro-inflammatory cytokines. This causes
skin inflammation with the involvement of keratinocytes,
which is followed by epidermal changes, including spon-
giosis and, macroscopically, to the development of scales,
vesicles or pustules [21]. Thus, immunologic mechanism
responsible for ACD rely on the production of inflamma-
tory cytokines by allergen-specific T cells, while regulatory
cytokines are thought to down-modulate the allergic re-
sponse. Previous studies have shown a relationship be-
tween the profile of cytokines induced by T cells and the
presence of a skin reactivity to PPD, suggesting that IL-10
production exerts a “protective” effect while IFN-γ in-
duces a “reactive” response [17,22,23]. These data support
the hypothesis that a regulatory mechanism mediated by
IL-10 contributes to the control of the clinical manifesta-
tions in response to allergens [24].
At present, diagnosis of ACD is based on clinical history
and patch testing, the latter having major disadvantages,since interpretation of the results is subjective. Thus, the
development of an accurate and reliable in vitro assay
based on informative biomarkers and capable of predict-
ing the clinical outcome, still represents an unmet need
for the clinical and therapeutic management of ACD [25].
The present study was aimed at developing a laboratory
test capable of exploring the cytokine profiles expressed
by peripheral blood mononuclear cells (PBMC) in re-
sponse to PPD and another common active allergen such
as Nickel (Ni), and evaluating its specificity and sensitivity
as well as the potential for predicting the clinical outcome
in exposed subjects.Methods
Patients
PBMC were obtained from 31 subjects. Twenty-one of
them were hairdressers (13 women and 8 men). Eleven
of them attended the Allergy outpatient clinic presenting
moderate (n = 8) or severe (n = 3) symptoms of ACD,
while 10 subjects were asymptomatic. Ten healthy sub-
jects not occupationally exposed to PPD nor to Ni were
studied as controls. The mean age was 33.2 yrs, with a
range between 20–55. Subject’s description is summa-
rized in Table 1.
Patient assessment was based on the administration of
a questionnaire to collect information including occupa-
tional history, personal and familiar history of allergy
(asthma and/or allergic rhino-conjunctivitis with at least
one positive prick test reaction to relevant aeroaller-
gens), and dermatitis. None of the patients had recently
used immunosuppressive medication or underwent UV
radiation or suffered from acute inflammatory skin dis-
eases. Further, none of them had metal dental braces
neither the presence of tattoo.
An informed consent was obtained from all subjects
prior to the blood samples collection (Ethics Committee
approval N. 488/14 IFO, Istituti Fisioterapici Ospitalieri).Patch testing
Patch testing was performed by Finn Chambers® on
Scanpor® tape, with the European standard series of con-
tact allergens (Hermal Trolab, Reinbeck, Germany), in-
cluding 5% Nickel Sulphate hexahydrate (NiSO4 × 6H2O,
Merck, AG, Darmstadt, F.R.G) and PPD 1% (FIRMA,
Firenze, Italy; Chemotechnique Diagnostics, Vellinge,
Sweden) applied in petrolatum. All allergens were ap-
plied on the upper back and removed after 48 hr.
Patch test responses were examined on day 2 and de-
fined as strong (+++: oedema, erythema, papules and
vesicles), moderate (++: oedema, erythema and papules),
weak (+: oedema and erythema) or no reaction (neg) ac-
cording to the International Contact Dermatitis Research
Group guidelines [26].
Table 1 Clinical details of patients
Patients Age Sex Occupationally exposed ACD symptoms Patch test PPD Patch test Ni Other Patch test positivities
1 25 f Yes Severe +++ ++ parabens, colophony, disp yellow
13 26 f Yes Severe +++ ++ No
2 25 f Yes Severe ++ neg No
3 35 f Yes Moderate ++ neg No
4 55 f Yes Moderate ++ neg No
5 20 m Yes Moderate + neg No
14 31 m Yes Moderate ++ neg No
15 40 f Yes Moderate + neg No
10 25 f Yes Moderate neg + No
11 29 f Yes Moderate neg ++ No
12 26 f Yes Moderate neg + No
6 31 f Yes Asymptomatic neg neg No
7 41 f Yes Asymptomatic neg neg No
8 43 f Yes Asymptomatic neg neg katon
9 33 m Yes Asymptomatic neg neg No
20 41 f Yes Asymptomatic neg neg No
21 41 m Yes Asymptomatic neg neg No
22 33 m Yes Asymptomatic neg neg No
23 35 m Yes Asymptomatic neg neg No
24 32 m Yes Asymptomatic neg neg No
25 33 m Yes Asymptomatic neg neg No
26 35 f Not Asymptomatic neg neg No
27 41 f Not Asymptomatic neg neg No
28 43 f Not Asymptomatic neg neg No
29 38 f Not Asymptomatic neg neg No
30 38 f Not Asymptomatic neg neg No
31 37 f Not Asymptomatic neg neg No
32 25 f Not Asymptomatic neg neg No
33 23 m Not Asymptomatic neg neg No
34 24 m Not Asymptomatic neg neg No
35 25 m Not Asymptomatic neg neg No
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PBMC were isolated from 10 ml of heparinized blood,
collected 48 hrs after skin testing, by standard Ficoll
density-gradient centrifugation (Lympholyte-H solution
Cederlane, Ontario, Canada) and washed twice with PBS. Cell
aliquots were frozen in 90% heat inactivated Fetal Bovine
Serum (FBS, Euroclone) and 10% DMSO (Dimethylsulphoxide,
Sigma) and kept in liquid nitrogen.
ELISpot determination of cytokine profiles induced in
PBMC in response to allergens
Cytokine profiles were determined by Dual-Color Human
ELISpot assay, according to manufacturer’s instruction.
This test allow the simultaneous detection of IFN-γ andIL-10 secreting cells (R&D Systems, Europe Ltd., Abingdon,
UK). Briefly, PBMC (3 × 105 cells/well) from patients with
positive patch test to PPD or Ni or both, or with negative
patch test responses to either antigen, were incubated in
triplicate (37°C, 5% CO2) for 48 h, in the presence or in the
absence of the allergens, in RPMI-1640 medium containing
50 IU/mL penicillin, 50 μg/mL streptomycin, 2 mmol/
L L-glutamine, 1× mixture of nonessential amino acids, 10%
FCS (Gibco, BRL, UK). Red (IFN-γ) and blue (IL-10) spots
generated by cells producing cytokines were assessed and
recorded by an Automated ImmunoSpot Image Analyzer
Software (AELVIS Technologies, TEMA ricerche, Italy).
The number of spot forming cells (SFC) per 3 × 105
PBMC was used for the calculation of the Stimulation
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and unstimulated cells [24]. Responses were considered
positive when S.I. ≥3.
Allergens
The allergens used for in vitro stimulation of PBMC were:
Nickel sulphate hexahydrate NiSO4 × 6H2O, (Merck AG,
Darmstadt, F.R.G), PPD (Sigma-Aldrich, Chemie, Kappel-
weg, Schnelldorf, Germany). Triplicate wells containing
unstimulated cells or mitogen stimulated cells (PHA 1 μg/
ml, Sigma, Saint Louis, Missouri, USA) were the negative
and positive controls, respectively.Table 2 Individual values of IFN-γ or IL-10 spot forming cells
each experimental condition (W/O: medium alone; PHA: poly
IFN
Patients W/O PHA PHA S.I. Ni Ni S.I. PPD PPD S
1 27.00 187.33 6.94 151.67 5.62 117.00 4.33
13 17.67 120.33 6.81 42.00 2.38 188.67 10.68
2 16.50 124.67 7.56 31.33 1.90 65.33 3.96
3 27.67 285.00 10.30 38.00 1.37 143.00 5.17
4 45.00 360.33 8.01 41.00 0.91 183.33 4.07
5 35.50 285.00 8.03 30.00 0.85 127.67 3.60
14 15.67 102.33 6.53 31.67 2.02 79.33 5.06
15 20.67 91.33 4.42 18.67 0.90 37.33 1.81
10 14.67 197.33 13.45 61.67 4.20 27.33 1.86
11 22.00 155.33 7.06 84.33 3.83 25.67 1.17
12 23.51 160.67 6.83 95.33 4.05 47.67 2.03
6 12.00 92.00 7.67 13.67 1.14 5.67 0.47
7 23.33 190.00 8.14 22.00 0.94 9.67 0.41
8 21.67 198.33 9.15 15.33 0.71 57.00 2.63
9 10.33 70.33 6.81 9.67 0.94 16.33 1.58
20 17.00 72.33 4.25 18.67 1.10 10.67 0.63
21 7.33 204.67 27.91 8.33 1.14 15.00 2.05
22 26.00 195.67 7.53 35.33 1.36 59.67 2.29
23 14.00 72.00 5.14 12.00 0.86 18.33 1.31
24 10.00 97.00 9.70 17.00 1.70 8.33 0.83
25 17.67 207.33 11.74 26.67 1.51 13.00 0.74
26 18.33 208.67 11.38 18.67 1.02 27.33 1.49
27 3.67 70.33 19.18 9.67 2.64 9.00 2.45
28 21.67 228.67 10.55 22.00 1.02 30.67 1.42
29 32.67 68.33 2.09 13.00 0.40 16.00 0.49
30 20.00 206.00 10.30 19.33 0.97 33.33 1.67
31 25.00 66.33 2.65 26.33 1.05 23.00 0.92
32 6.00 36.00 6.00 15.33 2.56 17.67 2.94
33 9.33 51.00 5.46 9.67 1.04 16.33 1.75
34 32.00 208.67 6.52 19.33 0.60 29.00 0.91
35 5.33 70.33 13.19 6.33 1.19 14.33 2.69Stock solutions of PPD (1 M) were prepared dissolving
the commercial powder in cell culture medium/DMSO
(4:1, v/v) [27]. Preliminary titration experiments were
performed with PPD on 5 different donors by testing dif-
ferent concentrations (0.1-1-10-20-40-50-100 μM) of
PPD. The results were consistent with previous studies
[27] and showed that concentration over 50 μM were
toxic on PBMC (data not shown).
NiSO4 was resuspended before use, in sterile saline
solution at 2 mg/ml (Bioindustria, Novi Ligure, Italy)
and used at 20 μg/ml concentration as previously de-
scribed [24].(expressed as mean values of triplicate wells) and S.I. for
clonal stimulation 1 μg/ml; Ni 20 μg/ml, PPD 10 μM)
IL-10
.I. W/O PHA PHA S.I. Ni Ni S.I. PPD PPD S.I.
10.00 69.33 6.93 11.00 1.10 18.67 1.87
18.33 96.67 5.27 13.33 0.73 15.33 0.84
14.33 100.33 7.00 82.33 5.74 17.00 1.19
13.00 92.00 7.08 62.33 4.79 17.33 1.33
16.83 101.00 6.00 71.67 4.26 17.00 1.01
9.33 73.67 7.89 37.67 4.04 10.67 1.14
19.00 71.67 3.77 39.33 2.07 15.00 0.79
10.33 58.67 5.68 48.33 4.68 12.67 1.23
30.67 244.00 7.96 103.33 3.37 153.33 5.00
17.67 75.33 4.26 18.33 1.04 62.33 3.53
17.00 92.00 5.41 22.50 1.32 63.00 3.71
6.50 53.00 8.15 47.33 7.28 34.00 5.23
15.67 117.33 7.49 84.00 5.36 72.67 4.64
6.67 52.00 7.80 32.00 4.80 11.33 1.70
32.67 273.00 8.36 133.67 4.09 170.33 5.21
4.50 57.00 12.67 42.67 9.48 37.33 8.30
16.00 104.67 6.54 88.33 5.52 76.00 4.75
10.33 47.00 4.55 37.33 3.61 32.33 3.13
31.67 277.00 8.75 139.33 4.40 173.67 5.48
9.83 54.00 5.49 50.67 5.15 36.00 3.66
19.33 121.00 6.26 86.00 4.45 76.00 3.93
7.00 57.33 8.19 16.67 2.38 11.33 1.62
32.67 273.00 8.36 33.67 1.03 70.33 2.15
4.00 56.67 14.17 11.67 2.92 9.33 2.33
3.67 43.67 11.91 9.67 2.64 9.00 2.45
9.67 52.00 5.38 28.00 2.90 14.67 1.52
32.67 173.00 5.30 32.00 0.98 66.00 2.02
6.67 52.00 7.80 15.33 2.30 11.33 1.70
28.33 212.33 7.49 50.00 1.76 62.67 2.21
7.33 53.00 7.23 18.67 2.55 12.00 1.64
21.67 273.00 12.60 26.67 1.23 27.00 1.25
Table 3 PPD or Ni patch test results and respective S.I.
IFN-γ values in response to antigens
Patients Patch test PPD SI PPD Patch test Ni SI ni
1 +++ 4.33 ++ 5.62
13 +++ 10.68 ++ 2.38
2 ++ 3.96 neg 1.90
3 ++ 5.17 neg 1.37
4 ++ 4.07 neg 0.91
5 + 3.60 neg 0.85
14 ++ 5.06 neg 2.02
15 + 1.81 neg 0.90
10 neg 1.86 + 4.20
11 neg 1.17 ++ 3.83
12 neg 2.03 + 4.05
6 neg 0.47 neg 1.14
7 neg 0.41 neg 0.94
8 neg 2.63 neg 0.71
9 neg 1.58 neg 0.94
20 neg 0.63 neg 1.10
21 neg 2.05 neg 1.14
22 neg 2.29 neg 1.36
23 neg 1.31 neg 0.86
24 neg 0.83 neg 1.70
25 neg 0.74 neg 1.51
26 neg 1.49 neg 1.02
27 neg 2.45 neg 2.64
28 neg 1.42 neg 1.02
29 neg 0.49 neg 0.40
30 neg 1.67 neg 0.97
31 neg 0.92 neg 1.05
32 neg 2.94 neg 2.56
33 neg 1.75 neg 1.04
34 neg 0.91 neg 0.60
35 neg 2.69 neg 1.19
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ination (Limulus assay, BioWhittaker, Cambrex Company,
USA).
Statistical analysis
Descriptive statistic was used to summarize pertinent
study information. Comparisons between groups were
performed for different variables using the non paramet-
ric Mann–Whitney test. Agreement between the in vitro
results and clinical patch testing was estimated using the
Cohen’s kappa test. Specificity, sensitivity, negative and
positive predicted value (NPV and PPV, respectively) and
accuracy were calculated. Significance was assessed at
5% level. All analyses were performed by SPSS for Windows




Patch test was performed in all 31 subjects with or with-
out an history of occupational contact with PPD. Sub-
ject’s description and patch test results are detailed in
Table 1. According to the skin response, 8 subjects out
of 31 presented a skin response to PPD, while 5 subjects
had responses to Ni. Two subjects (Id: 1 and 13, respect-
ively) had positive responses to both allergens. All 20
asymptomatic subjects had negative patch test to PPD
and Ni.
Cytokine profiles in response to PPD and Ni
PBMC were incubated with PPD or Ni in short term
cultures and IFN-γ and IL-10 production was measured
by ELISpot assay. The results including SFC and S.I.
for each subject are shown in Table 2. In all cases
PHA stimulation (positive control) excluded individual
differences in the capability of producing a specific
cytokine as well as differences due to the quality of the
cryopreservation.
The production of IFN-γ was strictly associated with
a positive patch test result (Table 3). In fact, Positive
IFN-γ-responses (Index ≥ 3), in the presence of PPD or
Ni, were detected only in subjects with positive patch test
to PPD (Figure 1, panel A, P = 0.002) or to Ni (Figure 1,
panel C, P = 0.001), respectively.
All asymptomatic subjects with a history of contact
with PPD, however presenting a negative patch test, had
invariably an IL-10 response in the absence of IFN-γ
production. Healthy controls did not produce IFN-γ nor
IL-10 in response to stimulation with PPD or Ni.
As shown in Figure 1, IFN-γ or IL-10 production in re-
sponse to allergens appear mutually exclusive, while PHA
is capable of inducing both cytokines (Table 2). Statistical
analysis confirmed a significant negative correlation be-
tween IFN-γ and IL-10 production (P < 0.0001).No false-positive test results were found for PPD- neither
for Ni-induced increments, thus giving a 100% specificity
for both allergens. On the other hand, the sensitivity was
calculated as 87.5% (95% CI 65.9-100.0) for PPD and 80%
(95% CI 57.4-100.0) for Ni, respectively, hence the overall
test accuracy was of 93.3%.
A satisfactory concordance agreement between in vitro
and patch test results was also found (Cohen’s kappa test
0.84, P = 0.001).
The negative and positive predicted values were NPV =
87.5% and PPV = 100% for PPD and NPV = 90.9% and
PPV = 100%, for Ni, respectively.
Figure 1 Cytokine response elicited by PPD (panel A and B) or Ni (panel C and D) by ELISpot analysis in patch test negative or positive
patients, respectively. ELISpot results of detection of IFN-γ (panel A-C) or IL-10 (panel B-D) producing PBMC upon stimulation with Ni (20 μg/ml)
or PPD (10 μM) were expressed as the mean values of S.I. ± SD. S.I. Index value is expressed by the ratio between the number of spot forming cells
(IFN-γ and IL-10 producing PBMC) upon stimulation with the allergen and those present in the absence of stimuli (spontaneous cytokine production).
Positive IFN-γ-responses (Index≥ 3), in the presence of PPD or Ni, were detected only in subjects with positive patch test to PPD (panel A, P = 0.002) or
to Ni (panel C, P = 0.001), respectively.
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This study was aimed at exploring the cytokine responses
to specific allergens to evaluate whether the analysis of dif-
ferent cytokine profiles might provide the basis for a la-
boratory test capable of identify an allergic sensitization.
To date, the patch test is considered the gold standard
for identifying the causative agents responsible for con-
tact allergy [28]. However, its use is currently debated
[4,29]. In fact, although having a high sensitivity, patch
test has a major disadvantage, since interpretation of the
results is subjective. In addition it might be the cause of
a iatrogenic sensitization and, although rarely, induceadverse reactions [30]. Thought desirable, a laboratory test
capable of supporting the clinical and therapeutic manage-
ment of ACD it is not available, as yet.
Evidence indicate that the clinical manifestations of
ACD are associated with an inflammatory response to al-
lergens [22] while “regulatory” responses [21] are found in
allergen-responsive subject, which however do not develop
clinical symptoms. In fact, previous studies [24,31,32] sug-
gested that the production of specific cytokines in re-
sponse to antigenic stimulation can effectively modulate
the type of immune response. In particular, this paradigma
strongly suggests that IFN-γ production is associated with
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toms, while IL-10 production exerts a “protective” effect,
capable of controlling the hypersensitivity symptoms in
response to allergens [33]. This notion prompted us at
exploring the pattern of cytokine expression elicited
“in vitro” by contact allergens for the development of a
novel, simple, robust and reliable laboratory test for the
diagnosis and clinical profiling of ACD patients.
Other laboratory test, including the lymphocyte activa-
tion test (LAT) and lymphocyte transformation test
(LTT), have been proposed to investigate drug and contact
allergy [34-37]. These test are based on the detection of
antigen-driven T cell proliferation by [3H]-thymidine in-
corporation. However these approaches have shown a low
reproducibility, being therefore difficult to standardize,
and require radioactive compounds. Furthermore they do
not provide any predictive information about the potential
clinical outcome.
The present study was based on the assessment of the
cytokine profiles, namely IFN-γ and IL-10 production
by T cells, in response to allergens, using a Dual-Color
ELISpot assay [38,39].
We found a significant correlation between the ELISpot
results and the results gathered by patch testing (P = 0.001).
In particular, IFN-γ responses against PPD or Ni were
found only in subjects with a positive patch test to PPD
(P = 0.002) or to Ni (P = 0.001), respectively. On the con-
trary, all clinically asymptomatic subjects, with a history of
regular contact with PPD, had a negative patch test but
showed an IL-10 production in response to the allergens,
invariably in the absence of IFN-γ production, while, con-
trol healthy subjects did not produce IFN- γ nor IL-10.
These data confirm the presence of an anamnestic, though
clinically asymptomatic, response to the allergen even in
exposed subject which present with a negative patch test.
In fact, IFN-γ or IL-10 production appear mutually exclu-
sive, as confirmed by the statistical treatment of the data.
The assay gave a 100% specificity, a 80–87,5% sensitivity
and a 93.3% accuracy.
Conclusions
Although larger prospective-retrospective studies are ne-
cessary to validate the predictive potential of the test
and the possible indications for its use in clinical prac-
tice, the results suggest that this assay might offer a
complementary or, in some cases, alternative diagnostic
tool for the assessment of individuals with known or
suspected exposure to cutaneous allergens, particularly
in those cases of difficult application of patch test as in
patients with chronic skin inflammation, while helping
avoid the risk of both subjective interpretation and iatro-
gen sensibilization. In addition, it may be useful to reveal
previous exposure to allergens both in asymptomatic
and “allergic” individuals and might prove effective atpredicting the clinical outcome as well as at monitoring
the effect of therapeutic regimens.
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